Targeting transcription factors (e.g., STAT3, AR, and Nrf2) or epigenetic regulators (e.g., EZH2 and PRMT) could facilitate a strategy that induces ferroptosis while simultaneously inhibiting tumor-promoting immunity. The gene discussed is NFE2L2; the disease is neoplasm.